糖尿病治療薬CS-1036のハイブリッドプロセス開発
スポンサーリンク
概要
- 論文の詳細を見る
CS-1036 was a candidate compound for antidiabetic drug and synthesized with 3 key intermediates. The 5-membered iminocyclitol intermediate (C unit), one of the key intermediates for CS-1036 synthesis, was prepared by chemical synthesis in 12 steps previously. By using microbial metabolite, Nectrisine, as a starting material, the manufacturing process of C unit was shortened to 5 steps. Thus, the hybrid process between biological synthesis of Nectrisine and chemical synthesis from Nectrisine to C unit improved the productivity of C unit production dramatically. Nectrisine was originally purified with 2 ion-exchange chromatographies which posed disadvantage for large scale production to remove the residual protein impurities. The combination of denaturation by MeOH and crystallization from brine gave the important intermediate of C unit synthesis with high quality and yield without ion-exchange chromatographies.
- 社団法人 有機合成化学協会の論文
社団法人 有機合成化学協会 | 論文
- メソポーラスシリカの均一内部修飾反応と, その重合場としての応用
- 膜タンパク質との相互作用解明を志向した梯子状ポリエーテルの設計・合成・活性評価
- 安定な高性能p型有機半導体材料の開発
- フェナレニルを基盤とする非局在型一重項ビラジカルの化学
- 環境応答型芳香族アミド化合物の構造変換と動的制御